ARCALIS will exhibit a corporate booth and present a poster at the “SCARDA Joint Forum 2025 – Progress and Outcomes on Infectious Disease Vaccine Challenges, Toward Deepening Collaboration”, to be held on November 26. Dr. Yanwen Feng, Process Development Department, Development Headquarters, ARCALIS, will deliver the poster presentation.
We warmly invite all participants of the forum to visit our corporate booth and attend the poster presentation.

Forum Details
Date & Time: Wednesday, November 26, 2025, 9:30AM–6:00PM
Venue: Otemachi Place Hall & Conference 2nd Floor, Otemachi Place, 2-3-1 Otemachi, Chiyoda-ku, Tokyo
URL: https://www.amed.go.jp/news/event/scarda_forum.html

Poster Presentation
Lecture Title: A strategy to develop effective and safe mRNA-based therapeutics
Speaker: Yanwen Feng, Process Development Department, Development Headquarters, ARCALIS

Presentation Abstract:
ARCALIS is a CDMO specializing in mRNA-based therapeutics and vaccines, offering services from sequence design to commercial manufacturing. In partnership with Axcelead Drug Discovery Partners, Inc., the group company of Axcelead, Inc., ARCALIS also supports preclinical drug development, including animal studies for IND applications. Since 2024, ARCALIS has commercially produced self-amplifying mRNA (saRNA) for COVID-19 vaccines. In this presentation, we will introduce three proprietary technologies developed to enhance the safety and efficacy of mRNA therapeutics:
1, A novel design platform for self-amplifying RNA (saRNA)
2, HARNA^TM – an advanced method for mRNA sequence optimization
3, A strategy to reduce double-stranded RNA (dsRNA) impurities